未知生产厂商
BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
In radioligand binding studies, BL-1020 displayed strong interaction with dopamine receptors especially D and D (K of 0.27 nM and 0.17 nM respectively), the serotonin receptor 5-HY (K 0.25 nM) as well as moderate interaction with the GABAA receptor (K 3.29 microK).
Investigated for use/treatment in schizophrenia and schizoaffective disorders.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
